Drug Shortage Report for LABETALOL HYDROCHLORIDE INJECTION USP
Report ID | 77737 |
Drug Identification Number | 02231689 |
Brand name | LABETALOL HYDROCHLORIDE INJECTION USP |
Common or Proper name | LABETALOL HCl |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | LABETALOL HYDROCHLORIDE |
Strength(s) | 5MG |
Dosage form(s) | LIQUID |
Route of administration | INTRAVENOUS |
Packaging size | 20ml |
ATC code | C07AG |
ATC description | BETA BLOCKING AGENTS |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | |
Actual start date | 2019-02-20 |
Estimated end date | 2019-05-31 |
Actual end date | 2019-06-01 |
Shortage status | Resolved |
Updated date | 2019-06-28 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2019-06-28 | French | Compare |
v5 | 2019-06-28 | English | Compare |
v4 | 2019-05-10 | French | Compare |
v3 | 2019-05-10 | English | Compare |
v2 | 2019-03-05 | French | Compare |
v1 | 2019-03-05 | English | Compare |
Showing 1 to 6 of 6